Nuvectis Pharma NVCT
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 22nd percentile, 5-year average -7.4x
Near the bottom of its 5-year range · 10th percentile, 5-year average 14.4x
#4469 of 5328 stocks by PB (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 5.50 | – | 14.37 | 10% (cheaper than usual) | #4469 of 5328 (1 = cheapest) |
| PE | -10.12 | -14.50 | -7.38 | 22% (cheaper than usual) | – |
| PS | – | – | 0.00 | – | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NVCT.
Sign in to join the discussion.